Reshaping the Future of Immuno-Oncology: Johnson & Johnson Innovation Outlines Strategic Vision and Pipeline Advancements
In 2020, the global10 million peopleDeath from Cancer1; among the 19.3 million new cancer casesNearly half are from Asia. It is projected that by 2040, the annual number of new cancer cases worldwide will rise to28.4 million2. How to Address the High Incidence and Mortality Rates of Cancer, and Explore More EffectiveInnovative Therapies for Cancer Treatment, has become an important topic.
Tumor Immunology, is a field that leverages the human immune system toThe Discipline of Cancer Prevention, Control, and Elimination. In recent years, China andRising Number of Clinical Studies on Tumor Immunotherapy in the Asia-Pacific Region. In Asia, the prevalence of cancers driven by high-frequency somatic mutations—such as melanoma, lung cancer, bladder cancer, gastric cancer, and esophageal cancer—is also on the rise, and these cancers are more responsive to tumor immunotherapy. By the end of 2024, the oncology immunotherapy market in the Asia-Pacific region is projected to grow from approximately $15 billion in 2019 to around $28 billion.3
Under Johnson & JohnsonJanssen PharmaceuticalsHigh AttentionDevelopment Trends in Cancer Immunotherapy. With years of deep expertise in the field of cell therapy, we have developed novel agents for multiple myeloma and innovative therapeutics for other malignancies, including solid tumors; furthermore, by combining tumor immunotherapies with other modalities, we are investigating drug molecules across multiple therapeutic areas.
Johnson & Johnson InnovationDedicated toInnovation and Collaboration, to promote includingImmunotherapyInsideAdvances in Oncology Treatment。Stefan Hart, Senior Director of Oncology, Johnson & Johnson Innovative Medicine, Asia PacificStated: “At Johnson & Johnson Innovation, our early-stage innovation collaboration team employs a flexible, multi-pronged partnership model to meet the diverse development needs of our partners. We look forward to working hand in hand with our partners to address one of the most pressing healthcare challenges worldwide.”
Johnson & Johnson Innovation to Host Online Seminar on Tumor Immunology on June 23On June 23, Johnson & Johnson Innovation will host an online seminar focused on tumor immunology. During the event, R&D experts from Janssen will share updates on the progress of tumor immunology research and provide an in-depth analysis of Janssen’s desired collaboration directions and future prospects in this field. Additionally, experts from the Johnson & Johnson Innovation Early Stage Partnering team will outline the company’s key focus areas and strategies in tumor immunotherapy, and introduce its collaboration models with early-stage innovative enterprises.
Conference Language:English
Charles Drake
Global Vice President, Oncology Immunology, Janssen Research & Development
Stefan Hart
Senior Director, Oncology, Johnson & Johnson Innovative Medicine Asia Pacific
https://immunoOncologyinnovation.splashthat.com
Following the symposium, Janssen Innovation will also host one-on-one partner meetings to engage in in-depth discussions and exchanges with innovators who possess groundbreaking ideas and early-stage research projects. During this session, selected companies can interact with experts from the Janssen Innovation team on innovative solutions in oncology, covering areas including but not limited to malignant hematologic tumors, prostate cancer, and immunotherapy.
https://jnj-innovation.smapply.io/prog/oncology_AP
Reference Content:
1、 https://www.who.int/news-room/fact-sheets/detail/cancer
2、 “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, 2021, doi.org/10.3322/caac.21660.
3、 https://www.marketdataforecast.com/market-reports/apac-cancer-immunotherapy-market